Skip to main content
AmigoFish

ASCO 2026 Plenary: RASolute-302

From Two Onc Docs · · 11 min

This plays from the publisher's own server. We do not host a copy.

Open at the source

Not rated yet

Description

This week’s episode will be focusing on the 2026 ASCO Plenary that received a standing ovation, the RASolute 302 trial.

The RASolute 302 trial is a landmark phase 3 study demonstrating that daraxonrasib doubled overall survival compared to chemotherapy in previously treated (2L) metastatic pancreatic ductal adenocarcinoma (mPDAC).

Back to Two Onc Docs · Report a problem